The TNM classification is still crucial for our decision-making process in curable (local or locally advanced) non-small cell lung cancer (NSCLC). The N-stage has to be carefully assessed before deciding to start neoadjuvant or adjuvant therapy, said Dr Walter Weder (University Hospital Zurich, Switzerland). Invasive mediastinal staging is necessary in early stage lung cancer, in case of unclear stage after careful imaging, in case of doubt that a curative approach is reasonable due to the exact stage of the disease, or in case neoadjuvant therapy is planned for downstaging. However, mediastinal staging is invasive, which carries potential risks of morbidity and mortality, and may unnecessarily delay curative treatment. Decision on when to carry out invasive mediastinal staging may still vary among institutions and caregivers.
In 2015, the International Association for the Study of Lung Cancer Lung Cancer Staging Project made some proposals for the revisio...
please login to read the entire article:
You need to register to read the entire article, please do so now.
Table of Contents: ELCC 2019
Current Management of Early Stage NSCLC
Trial Data: Early Stage Lung Cancer
Immunotherapy in Stage 4 Lung Cancer
Trials: Immunotherapy in Stage 4 Lung Cancer
Implementation of Personalised Lung Cancer Care in Clinical Routine
Optimal Management of Brain Metastases in NSCLC
Small Cell Lung Cancer: New Targets
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.